The Impact of Aging, Psychotic Symptoms, Medication, and Brain-Derived Neurotrophic Factor on Cognitive Impairment in Japanese Chronic Schizophrenia Patients.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

1. An increase in plasma brain derived neurotrophic factor levels is related to n-3 polyunsaturated fatty acid efficacy in first episode schizophrenia: secondary outcome analysis of the OFFER randomized clinical trial.Psychopharmacology · 2019
   Trial
2. Effectiveness of Adding Metacognitive Training to Occupational Therapy in Patients With Schizophrenia Under Long-Term Hospitalization: A Pilot Randomized Controlled Trial.Cureus · 2025
   Article
3. High-Density Lipoprotein Correlates with Cognitive Functioning in Schizophrenic Women.Brain sciences · 2024
   Article
4. The Ethiopian Cognitive Assessment battery in Schizophrenia (ECAS): a validation study.Schizophrenia (Heidelberg, Germany) · 2024
   Article
5. The Influence of Electroconvulsive Therapy (ECT) on Brain-Derived Neurotrophic Factor (BDNF) Plasma Level in Patients with Schizophrenia-A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2023
   Review
6. Metabolic profile in first episode drug naïve patients with psychosis and its relation to cognitive functions and social cognition: a case control study.Scientific reports · 2023
   Article
7. Brain-derived neurotrophic factor (BDNF) in schizophrenia research: a quantitative review and future directions.AIMS neuroscience · 2023
   Review
8. Converging Evidence Points to BDNF as Biomarker of Depressive Symptoms in Schizophrenia-Spectrum Disorders.Brain sciences · 2022
   Article
9. Prevalence, profile and associations of cognitive impairment in Ugandan first-episode psychosis patients.Schizophrenia research. Cognition · 2022
   Article
10. Sex differences in association between cognitive impairment and clinical correlates in Chinese patients with first-episode drug-naïve schizophrenia.Annals of general psychiatry · 2021
    Article
11. Nature and Correlates of Executive Dysfunction in Schizophrenia: An Exploratory Study.Indian journal of psychological medicine · 2021
    Article
12. BDNF as a Biomarker of Cognition in Schizophrenia/Psychosis: An Updated Review.Frontiers in psychiatry · 2021
    Review
13. High Chili Intake and Cognitive Function among 4582 Adults: An Open Cohort Study over 15 Years.Nutrients · 2019
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

6 authors at 3 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as